Dar Zavain, a director at Recursion Pharmaceuticals, has reported the acquisition of 4,607 shares of Class A common stock in the company. This transaction, which took place on October 1, 2026, is part of the issuer's Outside Director Compensation Policy. The update highlights Dar Zavain's continued role within the company and reflects ongoing compensation practices in the life sciences sector.
Recursion Pharmaceuticals, Inc., identified by CIK 0001601830, is a company focused on biological products, specifically in the life sciences industry. The company was previously known as Recursion Pharmaceuticals, LLC, and has undergone a name change since its inception. The most recent filing was made on October 2, 2026, as a Form 4, indicating a change in ownership by a director.
According to the filing, Dar Zavain now owns a total of 245,371 shares following this transaction. The shares were acquired at no cost, as they were issued under the company's compensation policy for directors. This acquisition may influence the perception of leadership stability at Recursion Pharmaceuticals.
The filing does not specify what happens next regarding further transactions or changes in ownership. However, it is clear that Dar Zavain remains an active participant in the governance of Recursion Pharmaceuticals, which may have implications for the company's strategic direction.